Professor of Clinical Immunology and Chief Physician at Lund University. Member of the Royal Academy of Sciences (1997). Recipients of national and international awards. Founder and chairman of Hamlet BioPharma.
Magnus Nylén holds a BA degree from Boston University and has extensive experience from national and international capital markets including The Royal Bank of Scotland, Alfred Berg Fondkommission, HSBC and Aros Fondkommission. Since 2013, Magnus Nylén is one of the owners of Partner Fondkommission, with offices in Göteborg and Stockholm.
Bill received his PhD from Lund University and has since held professorships at both Lund University and Swedish University of Agricultural Sciences (SLU). Since 2006, he serves as Director of the Max Planck Institute for Chemical Ecology in Jena, Germany. He is also Honorary Professor at Friedrich-Schiller-Universität and guest professor at SLU.Between 2014 and 2020, he served as Vice President of the entire Max Planck Society. Bill has received numerous national and international awards, most recently The Gold Medal of the Royal Swedish Academy for Agriculture and Forestry and The Order of Merit of the Federal Republic of Germany. He is a member of several academies, among them The Royal Swedish Academy of Sciences and The German National Academy of Sciences Leopoldina. Through Bill, we have access to extensive international networks, along with his broad experience in taking scientific research to the commercial market.
Henrik Sundin is a lawyer by training and has extensive experience from the financial sector. He has held CEO positions and served as a board member of several companies in this sector. Henrik Sundin is also an active investor in a number of companies. Henrik Sundin brings expertise in areas of business development, strategy and capital market issues to the company. Henrik has been an investor in Hamlet BioPharma since the company’s IPO.
Jakob Testad has his education from the School of Economics and Business Administration at Lund University and has been involved in Hamlet BioPharma since the company’s IPO 2015. Jakob has been Chief Financial Officer of Hamlet BioPharma since 2023.